Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008141 | 0.81 | HTR6 (0.48) | GAAAKR1B1ALDH1A1CA12CA1 | |
| SCHEMBL22906062 | 0.78 | CA1 (0.44) | GAAKMT2AMEN1CA12CA1 | |
| SCHEMBL11639987 | 0.71 | ALDH1A1 (0.44) | GAAAKR1B1KMT2AMAPTMEN1 | |
| SCHEMBL4400955 | 0.71 | GAA (1.00) | GAARAPGEF4KMT2AMAPTMEN1 | |
| SCHEMBL170033 | 0.71 | GAA (1.00) | GAARAPGEF4KMT2AMAPTMEN1 | |
| SCHEMBL10067072 | 0.71 | GAA (1.00) | GAARAPGEF4KMT2AMAPTMEN1 | |
| Water SCHEMBL9619041 | 0.69 | GAA (0.94) | GAARAPGEF4KMT2AMAPTMEN1 | |
| SCHEMBL10605735 | 0.69 | GAA (0.73) | GAAAKR1B1RAPGEF4KMT2AMAPT | |
| SCHEMBL1097174 | 0.68 | GAA (0.52) | GAAAKR1B1RAPGEF4KMT2AMAPT | |
| SCHEMBL1976807 | 0.68 | GAA (0.52) | GAAAKR1B1RAPGEF4KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123981-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | NOVO NORDISK A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| EP-4090665-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11331369-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2021146488-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20200282016-A1 | Endoparasitic Depsipeptides | ZOETIS SERVICES LLC | 2020-09-10 | — | — | US | disclosed |
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-7335753-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060264385-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2006-11-23 | — | — | US | disclosed |
| US-7091196-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-20050197334-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2005-09-08 | — | — | US | disclosed |
| EP-1543017-A2 | BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Rib-X Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004029066-A2 | BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| US-4663461-A | Process for preparing 1-H-tetrazole-5-thiols | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-05 | — | — | US | disclosed |
| US-4526978-A | Process for preparing 1-H-tetrazole-5-thiols and intermediate compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | GAA 1117/4885AKR1B1 1513/4885RAPGEF4 2602/4885 |
| US-20060264385-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | GAA 1117/4885AKR1B1 1513/4885RAPGEF4 2602/4885 |
| US-20200282016-A1 | Endoparasitic Depsipeptides | VIP, PREP, NGLY1 | GAA 553/4885AKR1B1 1378/4885RAPGEF4 2575/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | GAA 3189/4885AKR1B1 540/4885RAPGEF4 3437/4885 |
| US-11331369-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | GAA 553/4885AKR1B1 1378/4885RAPGEF4 2575/4885 |
| US-20050197334-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | GAA 1117/4885AKR1B1 1513/4885RAPGEF4 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.